aTyr Pharma

#7305

Rank

$131.12M

Marketcap

United States

Country

Leadership team

Dr. Sanjay S. Shukla M.D., M.S. (Pres, CEO & Director)

Ms. Jill M. Broadfoot (Chief Financial Officer)

Ms. Nancy E. Denyes Krueger (Gen. Counsel & Corp. Sec.)

Products/ Services

Biotechnology, Pharmaceutical, Therapeutics

Headquarters

San Diego, California, United States

Established

2005

Company Registration

SEC CIK number: 0001339970

Traded as

LIFE

Social Media

URL

https://www.atyrpharma.com

Overview

Location

Recognition and Award

References

Summary

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

History

aTyr Pharma was founded in 2005 as a spin-off from The Scripps Research Institute. Since then, the company has raised more than $230 million to advance its research and development of medicines targeting the immune-modulatory pathways. aTyr has grown to now have a team of more than 50 researchers and business development professionals.

Mission

aTyr Pharma is dedicated to unlocking the power of Physiocrine biology to develop innovative medicines for patients with severe, rare diseases.

Vision

At aTyr Pharma, we envision a world in which no individuals with rare diseases go undiagnosed or untreated. We are committed to translating pioneering science into life-changing treatments to improve the lives of these patients.

Key Team

Dr. Ying J. Buechler Ph.D. (Exec. Director of Biologics Devel. & Manufacturing)

Ms. Ashlee Dunston (Director of Investor Relations & Corp. Communications)

Xiang-Lei Yang Ph.D. (Founder)

Dr. Melissa A. Ashlock (Sr. Advisor)

Mr. Peter Villiger (VP of Corp. Devel.)

Ms. Danielle Campbell (VP of Human Resource)

Dr. Leslie Nangle Ph.D. (VP of Research)

Recognition and Awards

aTyr Pharma was recognized as one of the Deloitte Technology Fast 500 Fastest Growing Companies in North America in 2017 and 2018, and was honored by San Diego Business Journal as one of the 2017 Most Admired Companies.